{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:44:42Z","timestamp":1761007482825,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2006,9,21]],"date-time":"2006-09-21T00:00:00Z","timestamp":1158796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:sc>L<\/jats:sc>\u2010dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D<jats:sub>3<\/jats:sub>\/D<jats:sub>2<\/jats:sub> receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D<jats:sub>2<\/jats:sub> vs. D<jats:sub>3<\/jats:sub> receptors, an issue we addressed with the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2013lesioned nonhuman primate model of Parkinson's disease. In <jats:sc>L<\/jats:sc>\u2010dopa\u2013primed animals, S32504 (0.16\u20132.5 mg\/kg p.o.) dose\u2010dependently enhanced locomotor activity. This action was abolished by the D<jats:sub>2<\/jats:sub> antagonist, L741,626 (2.5 mg\/kg), but potentiated by the D<jats:sub>3<\/jats:sub> antagonist, S33084 (0.63 mg\/kg). Both antagonists were inactive alone. In drug\u2010naive animals, a maximally effective dose of S32504 (2.5 mg\/kg p.o.) displayed pronounced antiparkinsonian properties from the third day of administration, and its actions were expressed rapidly and durably. Thus, on day 33, antiparkinsonian properties of S32504 were apparent within 5 minutes and present for &gt; 4 hours. Moreover, they were associated with neither wearing <jats:italic>off<\/jats:italic> nor significant dyskinesia. In conclusion, the novel D<jats:sub>3<\/jats:sub>\/D<jats:sub>2<\/jats:sub> agonist S32504 may offer advantages over <jats:sc>L<\/jats:sc>\u2010dopa in the treatment of newly diagnosed parkinsonian patients. Its actions are expressed primarily by activation of D<jats:sub>2<\/jats:sub>, not D<jats:sub>3<\/jats:sub>, receptors. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21106","type":"journal-article","created":{"date-parts":[[2006,9,21]],"date-time":"2006-09-21T18:57:52Z","timestamp":1158865072000},"page":"2090-2095","source":"Crossref","is-referenced-by-count":10,"title":["Antiparkinsonian effects of the novel D<sub>3<\/sub>\/D<sub>2<\/sub> dopamine receptor agonist, S32504, in MPTP\u2010lesioned marmosets: Mediation by D<sub>2<\/sub>, not D<sub>3<\/sub>, dopamine receptors"],"prefix":"10.1002","volume":"21","author":[{"given":"Michael P.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Rochat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Millan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00031-8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200111000-00002"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"issue":"2","key":"e_1_2_5_6_2","first-page":"20","article-title":"New drugs for the treatment of Parkinson's disease","author":"LeWitt PA","year":"2000","journal-title":"Pharmacotherapy"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(24)39333-4","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)\u2010receptors: II, functional and behavioral profile compared with GR218,231 and L741,626","volume":"293","author":"Millan MJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00353-4"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.062463"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.062414"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.062398"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.06.021"},{"issue":"7","key":"e_1_2_5_13_2","first-page":"7","article-title":"S33138, a novel and preferential antagonist at dopamine D3 receptors: functional profile in rodent models of the control of negative\u2010cognitive symptoms of schizophrenia","author":"Brocco M","year":"2004","journal-title":"Int J Neuropsychopharm"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)39332-2","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)\u2010receptors: I, receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626","volume":"293","author":"Millan MJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1148"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.022"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110203"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1149"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0022-3565(24)37098-3","article-title":"Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa\u2010primed 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine monkeys","volume":"283","author":"Blanchet PJ","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00581-0"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03491-4"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00916-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1770-x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.1945"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)02927-4"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-22-08305.2000"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/377424a0"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00548-1"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm875"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:42:01Z","timestamp":1760967721000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,21]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1002\/mds.21106"],"URL":"https:\/\/doi.org\/10.1002\/mds.21106","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2006,9,21]]}}}